Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen's Blincyto on path to broader ALL indication

This article was originally published in Scrip

Executive Summary

Amgen has a broader indication for its acute lymphocytic leukemia (ALL) treatment Blincyto (blinatumomab) in its sights after top-line Phase II data looked positive in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor ALL.

You may also be interested in...



Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha

Amgen Inc.'s first quarter revenue and earnings beat consensus estimates without a meaningful contribution from sales of the cholesterol-reducing biologic Repatha (evolocumab), but the company is pushing back against payers that are denying reimbursement to appropriate patients.

Spotlight On Novartis's Latest Potential Breakthrough Treatments

Last week, the Swiss major gave a glimpse into the next wave of innovation coming out of its labs in key areas such as osteoarthritis, pancreatic cancer and food allergy. Scrip has been taking a detailed look at the highlights.

Nine Endocrine And Metabolic Disease Drug Launches To Look Out For In 2022

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel